Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2020-01-10 Board/Management Inform…
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 8, 2020, for Xenon Pharmaceuticals Inc. The key content is the announcement of a change in the company's board of directors: the appointment of Dr. Clarissa Desjardins as a director and the resignation of Dr. Richard Scheller. It also details committee membership changes. There is no financial data, earnings information, or report publication mentioned. The primary focus is on board/management changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is about 4823 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the correct classification is MANG with high confidence.
2020-01-10 English
FORM 4 SUBMISSION
Director's Dealing
2019-12-17 English
FORM 4 SUBMISSION
Director's Dealing
2019-12-06 English
8-K NBIX LICENSE AGREEMENT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text describes a License and Collaboration Agreement between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc., detailing the terms of the agreement, financial terms, and collaboration programs. There is no indication that this is a full annual or quarterly report, audit report, earnings release, or other financial statement. Instead, it is an announcement of a material definitive agreement, which is typical content for an 8-K filing. According to the filing definitions, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes Form 8-K filings announcing material agreements.
2019-12-02 English
FORM 4 SUBMISSION
Director's Dealing
2019-11-22 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It relates to an at-the-market equity offering sales agreement for up to $50,000,000 of common shares by Xenon Pharmaceuticals Inc. The document includes detailed information about the offering, risk factors, use of proceeds, dilution, and other related legal and financial considerations. It is not a financial report like an annual or quarterly report, nor is it a transcript, management report, or governance document. It is a capital raising document describing the terms and conditions of a securities offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or certification.
2019-11-05 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.